Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.
Type
Public
HQ
Milton, GB
Founded
2001
Employees
296 (est)+7%
Oxford Immunotec was founded in 2001 and is headquartered in Milton, GB

Key People at Oxford Immunotec

Peter Wrighton-Smith

Peter Wrighton-Smith

CEO
Richard M. Altieri

Richard M. Altieri

CFO

Oxford Immunotec Locations

Milton, GB
Kohoku Ward, JP
Marlborough, US
Shanghai, CN

Oxford Immunotec Metrics

Oxford Immunotec Summary

Market capitalization

$317 M

Closing share price

$14.8
Oxford Immunotec's latest market capitalization is $317 M.

Oxford Immunotec Financials

Oxford Immunotec's revenue was £46.4 M in FY, 2015 which is 26.82% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£25.5 M£36.6 M£46.4 M

Revenue growth, %

43.5%26.8%

Cost of sales

£12.2 M£17.8 M£21.8 M

Gross profit

£13.3 M£18.9 M£24.6 M

Gross profit Margin, %

52.0%51.5%52.9%

Operating expense total

£17.7 M£34.9 M£42.4 M

Oxford Immunotec Market Value History

Oxford Immunotec News

Oxford Immunotec Company Life

You may also be interested in